Article thumbnail

Valsartan Improves b-Cell Function and Insulin Sensitivity in Subjects With Impaired GlucoseMetabolism A randomized

By Controlled Trial, Nynke J. Van Der Zijl, Chantalle C. M. Moors, Gijs H. Goossens, Marc M. H. Hermans, Ellen E. Blaak and Michaela Diamant


comes Research Trial demonstrated that treatment with the angiotensin receptor blocker (ARB) valsartan for 5 years resulted in a relative reduction of 14 % in the incidence of type 2 diabetes in subjects with impaired glucose metabolism (IGM). We investigated whether improvements in b-cell function and/or insulin sensitivity underlie these preventive effects of the ARB valsartan in the onset of type 2 diabetes. RESEARCH DESIGN ANDMETHODS—In this randomized controlled, double-blind, two-center study, the effects of 26weeks of valsartan (320mg daily; n = 40) or placebo (n = 39) on b-cell function and insulin sensitivity were assessed in subjects with impaired fasting glucose and/or impaired glucose tolerance, using a combined hyperinsulinemic-euglycemic and hyper-glycemic clamp with subsequent arginine stimulation and a 2-h 75-g oral glucose tolerance test (OGTT). Treatment effects were analyzed using ANCOVA, adjusting for center, glucometabolic status, and sex. RESULTS—Valsartan increased first-phase (P = 0.028) and second-phase (P = 0.002) glucose-stimulated insulin secretion compared with placebo, whereas the enhanced arginine-stimulated insulin secretion was comparable between groups (P = 0.25). In addition, valsartan increased th

Year: 2016
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://care.diabetesjournals.o... (external link)
  • http://care.diabetesjournals.o... (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.